Coeptis Therapeutics Inc Stock Price, News & Analysis

Coeptis Therapeutics (NASDAQ: COEP) announced a proposed transaction to acquire assets from Deverra Therapeutics, focusing on NK cell therapies for relapsed/refractory acute myeloid leukemia (AML) and respiratory infections. The agreement grants Coeptis exclusive negotiation rights until August 31, 2023, for two IND applications and Phase 1 trials involving NK cell therapy. This acquisition aims to enhance Coeptis' R&D capabilities and diversify its portfolio by integrating a proven allogeneic platform that requires no HLA matching. With anticipated Phase 1 AML trial data expected in 2H 2023, the deal could significantly expand Coeptis' technological footprint. If completed, Deverra's CSO, Dr. Colleen Delaney, is expected to join Coeptis as Chief Scientific and Medical Officer.

Coeptis Therapeutics Holdings (NASDAQ: COEP) has acquired exclusive rights to negotiate for the acquisition of VyGen-Bio, enhancing its oncology pipeline. The GEAR™ Platform and companion diagnostic technologies from VyGen-Bio will support the development of advanced cell therapies targeting CD38+ cancers, including multiple myeloma. Coeptis will initiate due diligence on VyGen-Bio’s assets, focusing on GEAR-NK cell therapy. The companies aim to leverage their collaboration to improve patient outcomes and expand treatment options in immuno-oncology. Successful completion of this transaction could mark a significant growth milestone for Coeptis.

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) announced that its SNAP-CAR technology was featured in a peer-reviewed article in the Journal of Translational Medicine on March 21, 2023. The SNAP-CAR platform, designed for multi-antigen targeting, aims to enhance the efficacy and safety of CAR T therapies for various cancers. The article highlights its potential to overcome limitations of current CAR T technologies by linking antibodies to universal CAR receptors. Coeptis plans to target HER2-expressing ovarian cancer as part of its first-in-human clinical development program, with the technology licensed from the University of Pittsburgh.

Coeptis Therapeutics (NASDAQ: COEP) has engaged Shareholder Intelligence Services (ShareIntel) for a comprehensive 12-month agreement to monitor and analyze trading patterns of its common stock. This partnership aims to identify illegal short selling and enhance shareholder protections. ShareIntel's DRIL-Down™ technology will track trading anomalies and provide valuable insights into market activities. Coeptis is committed to safeguarding shareholder interests and preventing market manipulation, according to CEO Dave Mehalick. The collaboration is part of Coeptis's broader strategy to protect its stock's value while advancing its cancer treatment platforms.

Coeptis Therapeutics has announced a sponsored research agreement with the University of Pittsburgh to advance the pre-clinical development of SNAP-CAR T cells targeting HER2-positive cancers. This collaboration aims to enable the filing of an Investigational New Drug (IND) application for clinical trials involving SNAP-CAR therapies. HER2 is overexpressed in about 28% of ovarian cancer tissues and 25% of breast cancer patients. The research will be led by Dr. Jason Lohmueller and Dr. Alexander Deiters, with the objective of optimizing SNAP-CAR's application in oncology, potentially offering breakthroughs in treatment options for solid tumors.

Coeptis Therapeutics (NASDAQ: COEP) has announced a strategic collaboration with IQVIA to advance its SNAP-CAR technology, a universal CAR T cell therapy platform. The partnership aims to identify target indications and initiate Investigational New Drug (IND) enabling activities for SNAP-CAR, which can be adapted for various cancer types, including hematologic and solid tumors. Coeptis plans to launch a first-in-human clinical program for SNAP-CAR, emphasizing its potential to treat cancers less accessible with current therapies. The collaboration leverages IQVIA's expertise to streamline the development process.

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) announced that its management will ring the Nasdaq Opening Bell on Nov. 16, 2022. CEO Dave Mehalick expressed excitement about the event, marking the completion of their business combination with Bull Horn Holdings Corp. The company aims to lead in cell therapy technologies for cancer, particularly through their SNAP-CAR platform and a new cell therapy targeting CD38-related cancers. Coeptis is also partnering with VyGen-Bio and researchers at the Karolinska Institutet to develop additional therapies and diagnostics.

Coeptis Therapeutics (NASDAQ: COEP) announced that its Scientific Advisory Board members, Hans-Gustaf Ljunggren and Evren Alici, participated in the Immuno Oncology Talks podcast discussing Natural Killer (NK) Cells. The company focuses on innovative cancer therapies, significantly featuring the CD38-GEAR-NK platform and CD38-Diagnostic tool, co-developed with VyGen-Bio and Karolinska Institutet. Company President David Mehalick highlighted the expertise of these board members as crucial in advancing Coeptis' commitment to effective cancer treatments.